ArticleEplasty2025
Replacing Bacitracin With Vancomycin in Adams Triple Antibiotic Solution for Irrigation in Breast Implant Reconstruction: A Retrospective Review of 277 Reconstructions.
Article in Eplasty, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Breast reconstruction following mastectomy commonly involves tissue expanders to create a suitable pocket for implantation. The use of triple antibiotic irrigation during tissue expander placement aims to reduce implant-related infections. Implant infections can lead to severe complications, often necessitating revision surgeries that may delay treatment of other conditions, such as cancer. For years, the most common solution used in breast pocket irrigation was the Adams solution, which comprises 80 mg gentamicin, 1 g cefazolin, and 50 000 U bacitracin in 500 mL of normal saline. However, the discontinuation of bacitracin has prompted the search for alternative formulations. Vancomycin, like bacitracin, has been shown to provide gram-positive coverage-only better. This study aims to evaluate the utility of a triple antibiotic solution (TAS) containing gentamicin, cefazolin, and vancomycin as a replacement for bacitracin in reducing infection rates following tissue expander placement. Methods: A single-center retrospective chart review was conducted, including 152 patients who underwent a total of 277 breast reconstructions with a TAS comprising 80 mg gentamicin, 1 g cefazolin, and 1 g vancomycin from March 2020 to June 2024. Demographic and clinical data, perioperative characteristics, and postoperative outcomes-including infection rates and culture results-were analyzed. Results: Infections occurred in 6 of 277 reconstructions (2.17% of implants). Methicillin-resistant Conclusions: This study highlights the potential utility of vancomycin as an acceptable alternative to bacitracin in triple antibiotic irrigation solution following tissue expander placement post-mastectomy. Additional research could help to further establish vancomycin's efficacy and safety. If validated, this approach could be a temporary alternative to the Adams solution until a better long-term strategy is identified.
Indexed as
Identifiers
41822402PMC12975522What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.